CRNX Latest Headlines

Crinetics Pharmaceuticals Raises $350 Million Through Public Offering—Focus on Endocrine Disease Innovation and Product Launch

Market Chameleon (Wed, 7-Jan 11:54 AM)

Crinetics Pharmaceuticals Announces $350 Million Equity Offering to Power Paltusotine Launch and R&D Pipeline

Market Chameleon (Wed, 7-Jan 7:53 AM)

Crinetics to Reveal Topline Results from Key Atumelnant Trial as Investors Eye Pipeline Progress

Market Chameleon (Mon, 5-Jan 11:54 AM)

Crinetics to Announce Phase 2 Cohort Results for Atumelnant and Share PALSONIFY Business Update—What Does This Mean for Endocrine Disease Treatment?

Market Chameleon (Mon, 5-Jan 7:55 AM)